Lotus Pharmaceutical Co (美時製藥) yesterday said it has signed an exclusive marketing agreement with Finland-based Orion Oyj for the distribution of its drugs to treat Parkinson’s disease in select Asian markets.
Lotus is to help Orion sell and distribute its branded drug Stalevo in Taiwan, Bangladesh, Hong Kong, Indonesia, the Philippines, South Korea and Vietnam, it said in a statement.
The company is also to sell Orion’s Comtan, another drug used to treat Parkinson’s disease, in Taiwan, Hong Kong, the Philippines and South Korea, it added.
Novartis Pharma AG currently holds the rights to sell and distribute the two proprietary drugs in those markets.
Those rights are to be transferred to Lotus in the third quarter of next year, the firm said.
“Novartis marketed Stalevo as a second-line treatment for Parkinson’s disease in those countries, which are recommended by doctors when the first-line therapy does not work,” Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
“However, Orion expects the drug to be used as a first-line treatment. That was the main reason why the Finnish company looked to change its marketing partner and sought our help,” Chen said.
Stalevo, which contains active pharmaceutical ingredients including levodopa, carbidopa and entacapone, has been used as a first-line drug in several overseas markets after Orion marketed the drug itself following its acquisition of the sales rights from Novartis last year, she added.
According to the agreement signed by Orion and Lotus, Orion would be responsible for manufacturing the products and the agreement would be in effect for five years following the first commercial sales.
Lotus expects sales of Stalevo to boost its revenue in the next few years, given the huge market for Parkinson’s treatment, Chen said.
The market was approximately US$1.04 billion across Asia last year and is estimated to increase at a compound annual growth rate of 6.8 percent, reaching US$1.44 billion by 2023, according to research firm Market Data Forecast, she said.
“Despite the heavy competition in Parkinson’s disease treatment, with many generic drugs in the market, we are confident about Stalevo and Comtan, as they are among the most frequently prescribed drugs,” Chen said.
Lotus sees Roche’s Madopar as Stalevo’s biggest rival in those Asian markets, but is not concerned about competition from generic drugs as many doctors and patients prefer branded drugs, she said.
While this is the first cooperation agreement between Lotus and Orion, the Taiwanese firm has partnerships with other companies to market their branded drugs, including Aclasta and Evista, which are used to treat osteoporosis, and Mercilon, a combined contraceptive pill.
With an approval rating of just two percent, Peruvian President Dina Boluarte might be the world’s most unpopular leader, according to pollsters. Protests greeted her rise to power 29 months ago, and have marked her entire term — joined by assorted scandals, investigations, controversies and a surge in gang violence. The 63-year-old is the target of a dozen probes, including for her alleged failure to declare gifts of luxury jewels and watches, a scandal inevitably dubbed “Rolexgate.” She is also under the microscope for a two-week undeclared absence for nose surgery — which she insists was medical, not cosmetic — and is
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
CHIP DUTIES: TSMC said it voiced its concerns to Washington about tariffs, telling the US commerce department that it wants ‘fair treatment’ to protect its competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reiterated robust business prospects for this year as strong artificial intelligence (AI) chip demand from Nvidia Corp and other customers would absorb the impacts of US tariffs. “The impact of tariffs would be indirect, as the custom tax is the importers’ responsibility, not the exporters,” TSMC chairman and chief executive officer C.C. Wei (魏哲家) said at the chipmaker’s annual shareholders’ meeting in Hsinchu City. TSMC’s business could be affected if people become reluctant to buy electronics due to inflated prices, Wei said. In addition, the chipmaker has voiced its concern to the US Department of Commerce
RSS